Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

  • There is currently no data for MSYS

Funding Update

13 Nov 2023 08:42

RNS Number : 2380T
Microsaic Systems plc
13 November 2023
Β 

13 November 2023

Microsaic Systems plc

("Microsaic" or the "Company")

Funding update

Β 

The Company announced on 3 November that it had begun a very significant cost reduction exercise which would include a substantially reduced operation cost base and the intention to reduce overheads by cancelling admission to trading of its shares on AIM ("Delisting") and conversion to a private company.

The Company has since been engaged in further funding discussions which involve raising funds subject to reinstatement of the Company's shares to trading on AIM. The Company is reviewing the proposals and will provide a further update on the resolutions to be put to shareholders to give effect to such proposals as soon as is reasonably practicable, along with an updated timetable for key events. This will include the revised timing for publication and posting of a circular to shareholders giving notice of a general meeting. The Directors believe that concluding a modest fundraise to support the retention of the AIM listing would be in the best interests of the Company in the medium term. Completion of such a fundraising remains conditional upon, inter alia, the publication of both the FY22 audited annual accounts on a going concern basis and the interim results for the six months ended 30 June 2023.

It is likely that, if proceeding with a fundraising subject to obtaining fresh shareholder authorities to allot new shares on a non-pre-emptive basis, the Company would still need to table an alternate resolution to approve Delisting in the event that the resolutions required to implement a fundraising were not passed. If the fundraising resolutions were to be approved, with firm commitments obtained from investors prior to the GM then being subject only to admission of the new shares (i.e. assuming reinstatement will occur), the Delisting resolution would be withdrawn from the business of the General Meeting.

Β 

Enquiries:

Microsaic Systems plc

Bob MooreExecutive Chairman

+44 (0)1483 751 577

Singer Capital Markets(Nominated Adviser & Joint Broker)

+44 (0)20 7496 3000

Aubrey PowellΒ / Angus Campbell

Β 

Β 

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker / James Pope

+44 (0) 20 3657 0050

Β 

Β 

Β 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information as stipulated under theΒ UKΒ version of the market abuse regulation no 596/2014 which is part of English law by virtue of the European Union (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain. The above named director takes responsibility for the release of this announcement.

Β 

About Microsaic (www.microsaic.com)

Microsaic listed on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested Β£30m over the last 20 years before and after the IPO, Microsaic has a robust patent portfolio in cutting-edge technology which enables analytical detection and characterisation at the point-of-need, whether within a human health environment, conventional laboratory setting, or within a bioprocessing facility for continuous mass spectrometer detection and monitoring of data at any step in the process workflow.

Β 

Microsaic's products and systems are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing, and point-of-need applications.Β Microsaic is an innovative company. Most recently the Company has developed an Acrylamide detector for use in the food industry and a ProteinID detector for the biopharma industry that will greatly reduce the manufacturing wastage costs by early detection of expensive product failure throughout the biopharmaceutical manufacturing process. For environmental monitoring, Microsaic has developed a method to analyse perfluoroalkyl-and polyfluoroalkyl (PFAS) substances, otherwise known as 'forever chemicals' using its mass spectrometer. This equipment can analyse water samples and determine whether PFAS concentrations are above legal thresholds with novel mobile testing capability. All of these new products are at the final stage of development and are expected to be released to the market in 2024.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
UPDUOOWROKUAARA
Date   Source Headline
24th Nov 20222:00 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSHalf-year Report
13th Sep 20227:25 amRNSSupply of mass spectroscopy services to DeepVerge
22nd Aug 20227:00 amRNSPartnership with Kingfield Electronics
5th Jul 20224:41 pmRNSSecond Price Monitoring Extn
5th Jul 20224:35 pmRNSPrice Monitoring Extension
5th Jul 20222:06 pmRNSSecond Price Monitoring Extn
5th Jul 20222:01 pmRNSPrice Monitoring Extension
4th Jul 20224:43 pmRNSReplacement: Trading Update
1st Jul 20222:09 pmRNSHolding(s) in Company
30th Jun 202212:11 pmRNSResult of AGM
30th Jun 20227:00 amRNSTrading Update
1st Jun 20227:00 amRNSPosting of Annual Report & Notice of AGM
30th May 20227:00 amRNSFinal Results
19th Apr 20227:00 amRNSManufacturing Services Framework Agreement
28th Mar 20227:30 amRNSUpdate on Microsaic's miniaturised technology
15th Mar 20227:00 amRNSBoard Appointment and Strategic Update
8th Mar 20224:35 pmRNSPrice Monitoring Extension
7th Mar 20222:05 pmRNSSecond Price Monitoring Extn
7th Mar 20222:00 pmRNSPrice Monitoring Extension
21st Feb 20221:31 pmRNSHolding(s) in Company
17th Feb 20222:45 pmRNSHolding(s) in Company
16th Feb 202211:06 amRNSSecond Price Monitoring Extn
16th Feb 202211:00 amRNSPrice Monitoring Extension
14th Feb 20227:00 amRNSDirector Dealing, Issue of Equity and TVR
28th Jan 20227:00 amRNSResignation of Chief Executive Officer
12th Jan 20224:43 pmRNSHolding(s) in Company
10th Jan 20223:30 pmRNSInvestor Presentation
10th Jan 20227:00 amRNSTrading Update
7th Jan 20222:06 pmRNSSecond Price Monitoring Extn
7th Jan 20222:00 pmRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSFurther order from DeepVerge
12th Nov 20217:00 amRNSNew compact screening platform
5th Nov 202110:12 amRNSHolding(s) in Company
27th Oct 20217:00 amRNSLaunch of technology for scaling drug manufacture
22nd Oct 20217:00 amRNSBoard Change
21st Oct 20217:00 amRNSUpdate on DeepVerge Collaboration
28th Sep 20214:30 pmRNSHolding(s) in Company
27th Sep 20217:00 amRNSInterim Results
24th Sep 20217:00 amRNSSigning of agreement to support China operations
22nd Sep 202111:06 amRNSNotice of Results and Investor Presentation
27th Aug 20214:40 pmRNSSecond Price Monitoring Extn
27th Aug 20214:35 pmRNSPrice Monitoring Extension
23rd Aug 20217:00 amRNSDeepVerge Collaboration for Water & Soil Analysis
9th Aug 20217:00 amRNSHeads of Terms signed with manufacturer in China
6th Jul 202111:55 amRNSInvestor Presentation
6th Jul 20217:00 amRNSTrading update for H1 2021
5th Jul 20219:50 amRNSHolding(s) in Company
2nd Jul 20217:00 amRNSDevelopment of real-time monitoring solution
17th Jun 202110:54 amRNSResult of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.